Sweden's Sedana Medical Q4 sales rise on EU growth

Sedana Medical AB (publ)

12/02/2026 06:17

Overview

Sweden's medtech firm Q4 net sales rose 5% yr/yr

Q4 EBITDA turned positive, improving from a loss last year

Company reported a net loss for Q4 2025

Outlook

Sedana Medical plans to submit NDA for US approval mid-year 2026

Company sees US market as largest growth opportunity post-approval

Sedana Medical aims for US launch as early as 2027

Result Drivers

EX-US PROFITABILITY - Achieved positive EBITDA in ex-US business due to operating model transformation and acquisition of Innovatif Cekal

SALES GROWTH - Strong sales in Spain, UK, and France drove growth despite lower ICU occupancy in Germany

US APPROVAL PROGRESS - Reduced risks for US approval with successful trials and FDA interactions

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Sales
SEK 51.80 mln
Q4 Adjusted EPS
-SEK 0.10
Q4 Net Income
-SEK 10.10 mln
Q4 Cash Flow From Operating Activities
SEK 200,000
Q4 EBITDA
SEK 100,000
Q4 EBIT Margin
-12.00%


Analyst Coverage

The one available analyst rating on the shares is "buy"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Press Release: ID:nMFN9Pr0Fz

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)